PMID- 35293283
OWN - NLM
STAT- MEDLINE
DCOM- 20220426
LR  - 20220716
IS  - 2165-5987 (Electronic)
IS  - 2165-5979 (Print)
IS  - 2165-5979 (Linking)
VI  - 13
IP  - 4
DP  - 2022 Apr
TI  - Magnesium isoglycyrrhizinate suppresses bladder cancer progression by modulating 
      the miR-26b/Nox4 axis.
PG  - 7986-7999
LID - 10.1080/21655979.2022.2031677 [doi]
AB  - Magnesium isoglycyrrhizinate (MI), a magnesium salt of 18alpha-GA stereoisomer, has 
      been reported to exert efficient hepatoprotective activity. However, its effect 
      on bladder cancer remains unclear. The study explored the effects of MI on the 
      growth, colony formation, apoptosis, invasion, and migration of bladder cancer 
      cells (HTB9 and BIU87 cells). Typical apoptotic changes of bladder cancer cells 
      such as nuclear concentration and fragmentation were observed using Hoechst 
      staining. The effects of MI on the expression levels of microRNA-26b (miR-26b), 
      NADPH oxidase 4 (Nox4), nuclear transcription factor-kappaB (NF-kappaB), and hHypoxia 
      inducible factor-1alpha (HIF-1alpha) were detected using qRT-PCR and Western blot. The 
      potential targets of miR-26b were predicted using Targetscan, and their 
      interactions were determined by luciferase reporter assay. A xenograft mouse 
      model was established to evaluate the anti-tumor effects of MI in vivo. MI 
      significantly suppressed the proliferation, colony formation, invasion, and 
      migration and induced apoptosis of human bladder cancer cells, and MI 
      significantly increased miR-26b expression. Nox 4 was identified to be a direct 
      target of miR-26b. MiR-26b mimics significantly decreased the relative luciferase 
      activity of wild type (WT) Nox 4 but not mutant type (MUT) Nox4. Meanwhile, MI 
      markedly downregulated the expression levels of Nox4, NF-kappaB, and HIF-1alpha both in 
      vitro and in vivo. Moreover, MI inhibited xenograft tumor growth in vivo and 
      decreased the expression of Nox4, NF-kappaB, and HIF-1alpha. Overall, MI showed a potent 
      anti-tumor effect against bladder cancer partially via modulating the 
      miR-26b/Nox4 axis.
FAU - Yuan, Zhihao
AU  - Yuan Z
AD  - Department of Emergency, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, P. R. China.
FAU - Guo, Guancheng
AU  - Guo G
AD  - Department of Emergency, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, P. R. China.
FAU - Sun, Guifang
AU  - Sun G
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, P. R. China.
FAU - Li, Qi
AU  - Li Q
AD  - Department of Urology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, P. R. China.
FAU - Wang, Lihui
AU  - Wang L
AD  - Department of Urology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, P. R. China.
FAU - Qiao, Baoping
AU  - Qiao B
AUID- ORCID: 0000-0003-0334-4629
AD  - Department of Urology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, P. R. China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Bioengineered
JT  - Bioengineered
JID - 101581063
RN  - 0 
      (18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate 
      magnesium tetrahydrate)
RN  - 0 (MIRN26A microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (NF-kappa B)
RN  - 0 (Saponins)
RN  - 0 (Triterpenes)
RN  - EC 1.6.3.- (NADPH Oxidase 4)
RN  - EC 1.6.3.- (NOX4 protein, human)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Humans
MH  - Mice
MH  - *MicroRNAs/genetics
MH  - *NADPH Oxidase 4/genetics
MH  - NF-kappa B/genetics/metabolism
MH  - *Saponins/pharmacology
MH  - *Triterpenes/pharmacology
MH  - *Urinary Bladder Neoplasms/drug therapy/genetics
PMC - PMC9161837
OTO - NOTNLM
OT  - Magnesium isoglycyrrhizinate
OT  - Nox4/ NF-kappaB/HIF-1alpha
OT  - apoptosis
OT  - bladder cancer
OT  - miR-26b
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/03/17 06:00
MHDA- 2022/04/27 06:00
PMCR- 2022/03/16
CRDT- 2022/03/16 08:43
PHST- 2022/03/16 08:43 [entrez]
PHST- 2022/03/17 06:00 [pubmed]
PHST- 2022/04/27 06:00 [medline]
PHST- 2022/03/16 00:00 [pmc-release]
AID - 2031677 [pii]
AID - 10.1080/21655979.2022.2031677 [doi]
PST - ppublish
SO  - Bioengineered. 2022 Apr;13(4):7986-7999. doi: 10.1080/21655979.2022.2031677.